The European School of Multimodality Imaging & Therapy (ESMIT)

Parathyroid Imaging (Self-paced)
2025-06-01 00:00 - 23:59 (Europe/Vienna) | Online
UEMS EACCME has granted the accreditation of 2.5 CME credits for this event.

This self-paced online course will offer a comprehensive exploration of the anatomy, physiology, and diagnostic tools related to parathyroid glands disorders. The course will cover a range of topics, including the regulation of parathyroid hormone (PTH) secretion and his mechanisms of action, etiology, clinical manifestations, and notably the diagnostic approaches ( laboratory and imaging), and treatment modalities especially concerning hyperparathyroidism.

Save yourself a seatEnter the eLearning store to register for the course. Having trouble? See the short tutorial here. Register now!

Learning Objectives

Attendees will gain insights into structure and function of the parathyroid glands, earning about etiology, clinical manifestations, diagnostic approaches focused on nuclear medicine and radiological techniques and treatment modalities of hyperparathyroidism. Through lectures, and case studies, participants will acquire the knowledge and skills necessary to diagnose and manage parathyroid disorders.

Target audience

This course is designed for Nuclear Medicine Physicians, Endocrinologists and Radiologists.

ProgrammeClick to see the Preliminary Programme. Please note, that it may be subject to change at any time. Programme

Faculty

Luca GiovanellaZurich, Switzerland

Murat TuncelAnkara, Türkiye

Michael KreisslMagdeburg, Germany

Petra PetranovicZagreb, Croatia

Registration Details

Registration Fee

Course Fee Free

myEANM accountLog into your myEANM account or create a new one.

ESMIT eLearningAccess the eLearning platform. You can also navigate to it directly from your myEANM database: ESMIT→ESMIT Registrations

eLearning Course StoreEnter the course store, make your selection and check out.

Enroll yourselfFind your desired course under ‘Online Courses’

Enjoy!Once enrolled, you get full access to the course contents on the ESMIT eLearning platform

Event Overview

Bringing Alpha Therapies into Clinical Practice
2025-06-01 00:00 - 23:59 | Online
UEMS EACCME has granted the accreditation of 3 CME credits for this event.

This online course offers a comprehensive introduction to alpha therapy in nuclear medicine, with a focus on the fundamental principles and clinical applications of Alpha-Therapy in the fields of Radiopharmaceutical Sciences, Oncology and Dosimetry. Alpha Therapy is a cutting-edge cancer treatment using alpha radiation. It represents a form of targeted radionuclide therapy that uses alpha-emitting radioisotopes to deliver lethal doses of radiation directly to cancer cells while sparing healthy tissues. It is highly efficient and lately increasingly explored for scientific purposes in the oncologic domain . With this course we aim at bringing Alpha Therapies into clinical practice through various, relevant presentations. A panel of experts and EANM members will update you on the type of alpha-emitting radioisotopes available, describing all important steps required for production and radiopharmaceutical development. The advantages, but also the challenges related to the use of Alpha therapy will amply be discussed and supported by clinical examples. You will be initiated in the existing and ongoing therapeutic trials, with the best yet to come. Dosimetry will play a pivotal role in this course, underlying its role in clinical practice. Finally, The Alphamet project will be presented, allowing you to get updated with the latest insights from Theranostics.

RPH

Targeted Alpha Therapy (TAT) represents a cutting-edge advancement in cancer treatment, harnessing the potent, cell-killing power of alpha particles to precisely destroy malignant cells while minimizing damage to surrounding healthy tissue. This part of the course course explores the transformative potential of TAT, highlighting its exceptional potency, unique ability to overcome radio-resistance, and its role in modern theranostics. You’ll gain insight into the selection of optimal alpha-emitting radionuclides, the biological advantages of short-range high-energy emissions, and the complex challenges involved in the development, production, and clinical translation of these innovative therapies. Join us to deepen your knowledge and be part of the future of targeted radiopharmaceuticals in oncology.

Oncology

In this part of the course, participants will explore the main advantages of alpha-emitting radionuclides in oncology, while also gaining an understanding of the clinical challenges associated with their use. You will become familiar with the key clinical aspects of Alpha-Therapy, supported by real-world perspectives and case insights. The course also highlights current and upcoming therapeutic trials, providing valuable knowledge on the future direction of this rapidly evolving field.

Dosimetry

Participants will begin by exploring the basic concepts of dosimetry with alpha emitters, highlighting key differences from beta emitter dosimetry. The course then delves into the clinical relevance of alpha dosimetry, demonstrating how accurate dose assessments can inform and optimize the management of patients undergoing treatment with alpha radiotherapeutics. In addition, the course presents the Alphamet project, a major European initiative that addresses the specific metrological challenges associated with targeted alpha therapies. By examining the goals and contributions of Alphamet, learners will gain insight into how this research supports the safe and effective integration of alpha therapy into routine clinical practice.

Save yourself a seatEnter the eLearning store to register for the course. Having trouble? See the short tutorial here. Register now!

Learning Objectives

Target Audience

To gain an overview of the main advantages of Alpha-radionuclides

To learn about the challenges of alpha emitters, complex production; transport issues, waste management and handling

To get insights on radiobiology: radiotoxicity & effectiveness

To have a comprehensive review of research candidates

To provide an overview of the main advantages when using Alpha-Therapy in clinical practice

To learn about the clinical challenges when using Alpha-Therapy

To get insights into current and future trials focusing on Alpha-Therapy

To learn the most basic aspects about dosimetry of alpha emitters showing the main differences with dosimetry of beta emitters

To learn how dosimetry results could be used in the management of patients treated with radiopharmaceuticals that include alpha emitters

To learn on the Alphamet project, which addresses the unique and unmet metrological challenges of targeted alpha therapies, contributing to their safe and optimised implementation into routine clinical practice

Nuclear medicine physicians, radiologists, medical oncologists, urologists, radiation oncologists, medical physicists, biologists, researchers

Radiochemists, radiopharmacists, physicists, medical physicists, biologists

ProgrammeClick to see the full event programme. View the Programme

Faculty

Dana NiculaeSpeaker

Marianna TosatoSpeaker

Pablo Mínguez GabiñaSpealer

Ana Denis-BacelarSpeaker

Emma AnaheimSpeaker

Wolfgang FendlerSpeaker

Mike SathekgeSpeaker

Joe O’SullivanSpeaker

Janke KleynhansSpeaker

Mathias ZacherlSpeaker

Daniela Oprea-LagerSpeaker

Registration Details

myEANM accountLog into your myEANM account or create a new one.

ESMIT eLearningAccess the eLearning platform. You can also navigate to it directly from your myEANM database: ESMIT→ESMIT Registrations

Enroll yourselfFind your desired course under ‘Online Courses’

Enjoy!Once registered, you get full access to the course contents on the ESMIT eLearning platform

Event Overview

GMP for Radiopharmaceuticals
2025-06-05 09:00 - 2025-06-06 16:00 | Future Health Lab, Alfred-Adler-Straße 1, Vienna, 1100, Austria
The GMP guidelines provide minimum requirements that a manufacturer of radiopharmaceuticals must meet to assure that their products are consistently high in quality, from batch to batch, for clinical use.

The Basics of cGMP is a 2 days on-site ESMIT course, providing guidance through EU-cGMP regulation for manufacturing, testing, and quality assurance of radiopharmaceuticals in order to ensure that a manufactured product is safe for human use. Principles regarding facilities, equipment qualification, controlled environmental conditions, processes and methods validation, standard operation procedures and user specific requirement, risk assessment, and specifications will be detailed. Also, the main components of investigational new drug and marketing authorisation dossiers will be discussed.

Register nowThe registration is closed. Please contact us at esmit@eanm.org if you still want to register.

Learning Objectives

General knowledge regarding GMP and cGMP for Radiopharmaceuticals principles and guidelines.

Target Audience

Radiopharmacists and radiochemists in translational research, hospital radiopharmacy and radiopharmaceutical production centres.

ProgrammeView the Programme

Faculty

Dana NiculaeSpeakerBucharest, Romania

Philip ElsingaSpeakerGroningen, Netherlands

Antero AbrunhosaSpeakerCoimbra, Portugal

Registration Details

Registration FeeMode of PaymentCancellation Policy

Course Fee € 950.-

Registration Fee includes:

Electronic Course Book, including all Slides

Coffee & Lunch Breaks

Registration Fee does NOT include:

Travel to the Venue

Accommodation

Registration fees need to be paid 1 week prior to the event. In case the payment is not received by this deadline, the registration needs to be cancelled. Payment can be settled by Credit Card Cheques will not be accepted

Cancellations must be notified in writing to the EANM Office. Telephone cancellations cannot be accepted. Substitutions will be accepted if the name and e-mail address of the substitute are sent to the EANM Office 4 weeks prior to the event. In the case of cancellation 4 weeks before the course, we will refund you the fee less a € 100,- administration charge. After this date, we cannot grant any refund for cancellations. Any refund will take place after the respective course. EANM will not be held liable for cancellation fees of hotels, airlines or other means of transportation.

Cardiac Amyloidosis Imaging: Do We Need Quantification?
2025-06-13 13:30 - 14:30
This webinar provides an overview of the diagnosis of cardiac amyloidosis in nuclear cardiology . Background information on amyloidosis in general is presented and typical disease manifestations are discussed. Furthermore, the significance of cardiac amyloidosis will be discussed in detail and possible therapeutic options will be explained. In this context, the relevance of quantification to characterize disease and how to assess reliably the effects of therapy are presented.

Register nowEnrol in the live webinar now for free! Register now

Learning Objectives

To gain a insight into the disease of amyloidosis and in particular the cardiac involvement of amyloidosis.

To learn the possibilities of quantification of planar and SPECT studies in amyloidosis

Target Audience

Nuclear physicians, cardiologists, internists and radiologists who are interested in amyloidosis and want to deepen their knowledge of cardiac amyloidosis diagnostics and quantification

Faculty

Federico CaobelliSpeaker

Ian ArmstrongSpeaker

Carmela NappiModerator

Stephan NekollaModerator

Event Overview

Extravascular Administration in Diagnostic and Therapeutic Nuclear Medicine
2025-06-27 13:30 - 14:30
In nuclear medicine, diagnostic as well as therapeutic, radiopharmaceuticals are administered via an intravenous injection, in a majority of the procedures in a blood vessel at the crook of the arm or on the back of the hand. Occasionally, the injection fails, which results in the radiopharmaceutical ending up extravascularly. The consequence of this may be a locally high radiation dose at the injection site, in some situations high enough to cause severe tissue effects on the patient. Thus, it is important to recognize the problem and identify the cause in order to decrease the risk. Furthermore, the management of the situation after such an extravasation must be dealt with thoroughly and this has been the subject of lively debate in recent years. The parameters that have an impact on the radiation dose are among other things, the physical properties of the radionuclide, as well as the activity and volume of the radioactive substance retained in the surroundings of the blood vessel. In the case when most of the administered activity ends up extravascular, the quality of the diagnostic procedure or the effect of the treatment are negatively affected, which must be addressed.

Register nowEnrol in the live webinar now for free! Register now

Learning Objectives

The aim of this webinar is to highlight the risk and consequences of extravascular administration of radiopharmaceuticals as well as the management of the situation after an extravasation.

Target Audience

Physicists, Physicians, Technologists, Nurses

Faculty

Siria MediciSpeaker

Jochem van der Pol Speaker

Sigrid Leide SvegbornModerator

Event Overview

Alpha Emitters – The Roadmap of the Big Ones!
2025-07-04 13:30 - 14:30
The purpose of this seminar is to provide a comprehensive overview of radionuclide therapy using alpha-emitting isotopes, focusing on their current clinical and preclinical applications. It will explore the unique advantages of alpha emitters, such as their high linear energy transfer and short path length, which allow for precise tumor cell killing with minimal damage to surrounding tissue. The seminar will also address key challenges, including limited availability of suitable alpha-emitting radionuclides, complex radiochemistry, and safety concerns during production and handling. Emphasis will be placed on production routes, chelation strategies, and conjugation chemistry that enable targeted delivery to cancer cells. Finally, the session will critically evaluate the therapeutic potential and limitations of alpha therapy, highlighting areas for future research and clinical translation.

Register nowEnrol in the live webinar now for free! Register now

Learning Objectives

Participants will gain understanding of the advantages of alpha-emitters over beta emitter

Participants will be able to describe and explain challenges arising from applications of alpha-emitters

Target Audience

Radiochemist, Radiopharmacists, nuclear physicians with a research profile, medicinal chemistry researchers

Faculty

Matthias HerthSpeaker

Filipe ElvasSpeaker

Dana NiculaeModerator

Event Overview

Technical Aspects of Parenteral Administration of Radiopharmaceuticals to Oncological Patients
2025-08-29 13:30 - 14:30
For performing the PET/CT examination, the administration of radiopharmaceutical as unavoidable for imaging with PET. Inversely, the administration of contrast agent to improve the quality of CT part of PET/CT as optional. The accurate intravenous administration of diagnostic radiopharmaceutical (and optionally of contrast agent) may be challenging in some cases, in particular in patients with compromised peripheral venous access after several lines of treatments. In order to increase the patient comfort and to simplify the intravenous administration of medicines, several types of long-term venous access have been developed.

Register nowEnrol in the live webinar now for free! Register now!

Learning Objectives

To understand the different types of currently available long-term venous accesses

To understand the principles of safe and correct handling of long-term venous access in patient referred for PET/CT

Target Audience

Nuclear Medicine Professionals

Faculty

Eugenia TrigosoSpeaker

Sona BalogovaSpeaker

Conrad-Amadeus VoltinModerator

Event Overview

NucMed Essentials - MSK Basics
2025-09-01 00:00 - 23:59 | Online
UEMS EACCME has granted the accreditation of CME credits for this event.

Nuclear Medicine Essentials: The Basics of MSK provides a comprehensive introduction to musculoskeletal applications in nuclear medicine, focusing on both diagnostic and therapeutic techniques. Participants will explore the fundamental principles of bone scintigraphy, including its physiological basis, imaging protocols, and wide range of clinical applications, with emphasis on its continued importance in patient care. The course also delves into advanced imaging through NaF PET, highlighting its uptake mechanisms, technical considerations, and growing role in oncology and other clinical contexts. Building on these diagnostic foundations, the course transitions into therapeutic strategies, such as the use of Radium-223 in the treatment of bone metastases, with attention to efficacy, safety, and radioprotection measures.

Beyond theoretical understanding, the program emphasizes practical application and clinical relevance. Learners will gain exposure to cutting-edge research, evidence-based workflows, and therapeutic innovations in the field. Radiosynovectomy for arthritis treatment is presented as an important example of nuclear medicine’s therapeutic scope, with procedural insights and expected outcomes supported by real-world case demonstrations. Departmental video presentations supplement each topic, offering participants a unique opportunity to see workflows and protocols in practice. By the end of the course, attendees will not only understand the fundamentals of musculoskeletal nuclear medicine but also appreciate its evolving role in modern imaging and therapy.

Save yourself a seatEnter the eLearning store to register for the course. Having trouble? See the short tutorial here. Register now!

Learning Objectives

Target Audience

Understand the fundamentals of bone scan techniques:– Describe the theoretical considerations and acquisition protocols for bone scans.– Explain the clinical applications of bone scans across various pathologies.

Gain insights into NaF PET for bone imaging:– Summarize the theoretical considerations and acquisition protocols specific to NaF PET.– Recognize the essential applications of NaF PET in oncology and other clinical cases.

Explore therapeutic approaches for bone metastases using bone-seeking agents:– Review current theoretical knowledge and recent publications on the treatment of bone metastases.– Identify practical considerations and procedural steps involved in bone-seeking agent therapies.

Learn the application of radiosynovectomy in managing arthritis:– Describe the indications, procedures, and expected outcomes of radiosynovectomy for arthritis treatment.

Apply knowledge through visual and practical insights from real-world clinical settings:– Assess clinical workflows and procedural nuances via department video presentations for each session.

Nuclear Medicine Physicians and Residents

ProgrammeClick to see the full event programme. View the Programme

Faculty

Knut LiepeSpeaker

Jules Zhang-YinSpeaker

Paolo TurcoSpeaker

Registration Details

Registration Fee

Course Fee € 0.-

myEANM accountLog into your myEANM account or create a new one.

ESMIT eLearningAccess the eLearning platform. You can also navigate to it directly from your myEANM database: ESMIT→ESMIT Registrations

Enroll yourselfFind your desired course under ‘Online Courses’

Enjoy!Once registered, you get full access to the course contents on the ESMIT eLearning platform

Event Overview

Radiation Safety for Oncological Patients before and after Nuclear Medicine Procedures and Radiation Safety of Nursing Staff
2025-09-19 13:30 - 14:30
This webinar will emphasize the critical importance of radiation protection in safeguarding both the occupational health of care providers and the well-being of patients undergoing radionuclide therapy.

It will underscore the necessity of adhering to established guidelines and protocols when handling radioactive materials to ensure safety and treatment efficacy.

Furthermore, the session will explore the role of interprofessional collaboration and continuing education among health care providers in enhancing radiation safety practices. It will also present evidence-based strategies to mitigate patients’ symptoms associated with the adverse effects of radionuclide treatment.

Register now!Enrol in the live webinar now for free! Register now

Learning Objectives

To identify the primary steps for introducing newly hired health care staff to radionuclide therapy protocols and recognize the importance of continuous education in maintaining adherence to institutional safety and procedural standards.

To evaluate various educational methods and strategies used to train health care providers—including nurses, caregivers, seasonal workers, and clinical assistants—in the principles, procedures, and safety protocols of radionuclide therapy.

To demonstrate effective patient education techniques and symptom management strategies for individuals undergoing radionuclide therapy, with attention to minimizing adverse effects and enhancing patient comprehension.

To compare different radiation safety protocols and clinical guidelines associated with Lutathera and radioiodine therapies, with respect to implications for both patients and health care providers.

Target Audience

All health care providers involved in the care of oncological patients undergoing radionuclide treatment in clinical practice

Faculty

Lace MatarloSpeaker

Matthias Hellberg-NaegeleModerator

Sigrid Leide SvegbornSpeaker

Explainable AI
2025-10-24 13:30 - 14:30
The webinar will provide first the fundamentals and basics of explainable artificial intelligence, including the tools for interpretability of machine and deep learning models, as well as the explainability principles. Second, it will provide how these concepts are translated and applied to the development of AI-based models for nuclear medicine applications.

Register nowEnrol in the live webinar now for free! Register now

Learning Objectives

Attendees will be able to understand what are the concepts and methods that define explainable AI, including interpretability tools and algorithms, as well as explainability concepts to translate these to the end-users.

Attendees will be able to discover how these concepts can be used to facilitate the development, adoption and trust for end-users of AI-based models in nuclear medicine applications.

Target Audience

Nuclear medicine physicians, scientists and technologists interested in the application of artificial intelligence in nuclear medicine imaging applications.

Faculty

Neo Christopher ChungSpeaker

Clemens SpielvogelSpeaker

Mathieu HattModerator

Event Overview

Bringing Alpha Therapies into Clinical Practice
2025-10-30 08:00 - 2027-11-30 17:00 | Online
UEMS EACCME has granted the accreditation of 3 CME credits for this event.

This online course offers a comprehensive introduction to alpha therapy in nuclear medicine, with a focus on the fundamental principles and clinical applications of Alpha-Therapy in the fields of Radiopharmaceutical Sciences, Oncology and Dosimetry. Alpha Therapy is a cutting-edge cancer treatment using alpha radiation. It represents a form of targeted radionuclide therapy that uses alpha-emitting radioisotopes to deliver lethal doses of radiation directly to cancer cells while sparing healthy tissues. It is highly efficient and lately increasingly explored for scientific purposes in the oncologic domain . With this course we aim at bringing Alpha Therapies into clinical practice through various, relevant presentations. A panel of experts and EANM members will update you on the type of alpha-emitting radioisotopes available, describing all important steps required for production and radiopharmaceutical development. The advantages, but also the challenges related to the use of Alpha therapy will amply be discussed and supported by clinical examples. You will be initiated in the existing and ongoing therapeutic trials, with the best yet to come. Dosimetry will play a pivotal role in this course, underlying its role in clinical practice. Finally, The Alphamet project will be presented, allowing you to get updated with the latest insights from Theranostics.

RPH

Targeted Alpha Therapy (TAT) represents a cutting-edge advancement in cancer treatment, harnessing the potent, cell-killing power of alpha particles to precisely destroy malignant cells while minimizing damage to surrounding healthy tissue. This part of the course course explores the transformative potential of TAT, highlighting its exceptional potency, unique ability to overcome radio-resistance, and its role in modern theranostics. You’ll gain insight into the selection of optimal alpha-emitting radionuclides, the biological advantages of short-range high-energy emissions, and the complex challenges involved in the development, production, and clinical translation of these innovative therapies. Join us to deepen your knowledge and be part of the future of targeted radiopharmaceuticals in oncology.

Oncology

In this part of the course, participants will explore the main advantages of alpha-emitting radionuclides in oncology, while also gaining an understanding of the clinical challenges associated with their use. You will become familiar with the key clinical aspects of Alpha-Therapy, supported by real-world perspectives and case insights. The course also highlights current and upcoming therapeutic trials, providing valuable knowledge on the future direction of this rapidly evolving field.

Dosimetry

Participants will begin by exploring the basic concepts of dosimetry with alpha emitters, highlighting key differences from beta emitter dosimetry. The course then delves into the clinical relevance of alpha dosimetry, demonstrating how accurate dose assessments can inform and optimize the management of patients undergoing treatment with alpha radiotherapeutics. In addition, the course presents the Alphamet project, a major European initiative that addresses the specific metrological challenges associated with targeted alpha therapies. By examining the goals and contributions of Alphamet, learners will gain insight into how this research supports the safe and effective integration of alpha therapy into routine clinical practice.

Save yourself a seatEnter the eLearning store to register for the course. Having trouble? See the short tutorial here. Register now!

Learning Objectives

To gain an overview of the main advantages of Alpha-radionuclides

To learn about the challenges of alpha emitters, complex production; transport issues, waste management and handling

To get insights on radiobiology: radiotoxicity & effectiveness

To have a comprehensive review of research candidates

To provide an overview of the main advantages when using Alpha-Therapy in clinical practice

To learn about the clinical challenges when using Alpha-Therapy

To get insights into current and future trials focusing on Alpha-Therapy

To learn the most basic aspects about dosimetry of alpha emitters showing the main differences with dosimetry of beta emitters

To learn how dosimetry results could be used in the management of patients treated with radiopharmaceuticals that include alpha emitters

To learn on the Alphamet project, which addresses the unique and unmet metrological challenges of targeted alpha therapies, contributing to their safe and optimised implementation into routine clinical practice

Target Audience

Nuclear medicine physicians, radiologists, medical oncologists, urologists, radiation oncologists, medical physicists, biologists, researchers

Radiochemists, radiopharmacists, physicists, medical physicists, biologists

ProgrammeClick to see the full event programme. View the Programme

Faculty

Dana NiculaeSpeaker

Emma AnaheimSpeaker

Janke KleyhansSpeaker

Marianna TosatoSpeaker

Wolfgang FendlerSpeaker

Mathias ZacherlSpeaker

Pablo Mínguez GabiñaSpeaker

Mike SathekgeSpeaker

Daniela Oprea-LagerSpeaker

Ana Denis-BacelarSpeaker

Joe O’SullivanSpeaker

myEANM accountLog into your myEANM account or create a new one.

ESMIT eLearningAccess the eLearning platform. You can also navigate to it directly from your myEANM database: ESMIT→ESMIT Registrations

Enroll yourselfFind your desired course under ‘Online Courses’

Enjoy!Once enrolled, you get full access to the course contents on the ESMIT eLearning platform

Event Overview

NucMed Essentials - MSK Basics
2025-11-03 00:00 - 2027-11-30 23:59
UEMS EACCME has granted the accreditation of 5 CME credits for this event.

New ESMIT Learning format: Self-paced online course followed by a live session with the course faculty, where participants are able to ask their questions live!*

Nuclear Medicine Essentials: The Basics of MSK provides a comprehensive introduction to musculoskeletal applications in nuclear medicine, focusing on both diagnostic and therapeutic techniques. Participants will explore the fundamental principles of bone scintigraphy, including its physiological basis, imaging protocols, and wide range of clinical applications, with emphasis on its continued importance in patient care. The course also delves into advanced imaging through NaF PET, highlighting its uptake mechanisms, technical considerations, and growing role in oncology and other clinical contexts. Building on these diagnostic foundations, the course transitions into therapeutic strategies, such as the use of Radium-223 in the treatment of bone metastases, with attention to efficacy, safety, and radioprotection measures.

Beyond theoretical understanding, the program emphasizes practical application and clinical relevance. Learners will gain exposure to cutting-edge research, evidence-based workflows, and therapeutic innovations in the field. Radiosynovectomy for arthritis treatment is presented as an important example of nuclear medicine’s therapeutic scope, with procedural insights and expected outcomes supported by real-world case demonstrations. Departmental video presentations supplement each topic, offering participants a unique opportunity to see workflows and protocols in practice. By the end of the course, attendees will not only understand the fundamentals of musculoskeletal nuclear medicine but also appreciate its evolving role in modern imaging and therapy.

*The live follow-up session will only be held if there is interest – please submit your questions at the dedicated space on our eLearning platform. The date of the live session will be announced in due time.

Save yourself a seatEnter the eLearning store to register for the course. Having trouble? See the short tutorial here. Register now!

Learning Objectives

I. Understand the fundamentals of bone scan techniques:

Describe the theoretical considerations and acquisition protocols for bone scans.

Explain the clinical applications of bone scans across various pathologies.

II. Gain insights into NaF PET for bone imaging:

Summarize the theoretical considerations and acquisition protocols specific to NaF PET.

Recognize the essential applications of NaF PET in oncology and other clinical cases.

III. Explore therapeutic approaches for bone metastases using bone-seeking agents:

Review current theoretical knowledge and recent publications on the treatment of bone metastases.

Identify practical considerations and procedural steps involved in bone-seeking agent therapies.

IV. Learn the application of radiosynovectomy in managing arthritis:

Describe the indications, procedures, and expected outcomes of radiosynovectomy for arthritis treatment.

V. Apply knowledge through visual and practical insights from real-world clinical settings:

Assess clinical workflows and procedural nuances via department video presentations for each session.

Target Audience

Technologists, nuclear medicine physicians and residents

Faculty

Knut LiepeSpeaker

Jules Zhang-YinSpeaker

Paolo TurcoSpeaker

Nuclear Medicine-related Highlights from ESMO 2025
2025-11-07 13:30 - 14:30
This ESMO 2025 webinar will cover a range of topics, including the latest advancements treatment options, imaging modalities and performant tracers related to solid and liquid tumors. The focus of this Live event will be the recent advances in solid & liquid tumor treatment, clinical trials and emerging therapies, biomarkers in solid tumors and multidisciplinary approaches. The importance of collaboration among medical oncologists, radiologists, nuclear medicine physicians, pathologists and surgeons will be underlined, based on clinical examples. Challenges and opportunities in immunotherapy for solid tumors will also be addressed, with special attention for personalized treatment plans in specific cancers, like lung cancer, breast cancer, colorectal and prostate cancer.

Please note that the webinar will be recorded, and the recording will be available a few days after the session is over. You can find the recording on the ESMIT E-learning platform, under the webinar title. A handout of the presentation materials will also be available on the platform.

Register nowEnrol in the live webinar now for free! Register now

Learning Objectives

Attendees will get insight into recent advances in solid/ liquid tumor treatment

Attendees will be familiarized with the latest developments when diagnosing, staging and treating different types of solid and liquid tumors.

Target Audience

Fellows and Medical Specialists in Nuclear Medicine, Radiology, Medical Oncology, Urology, Surgery, Pathology and Radiation Oncology

Faculty

David KerstingModerator

Karolien GoffinSpeaker

Matthias EiberSpeaker

Event Overview

Paediatric Thyroid Cancer
2025-11-14 13:30 - 14:30
This webinar aims to underly the most relevant differences with the adults DCT regarding epidemiology, genetics, pathology, immunoistopathology, diagnostic tools and treatment, especially for RAI theranostic procedure. Additionally, the webinar will also go over the main GL recommendations, as well as present and discuss two emblematic or tricky cases.

Register nowEnrol in the live webinar now for free! Register now

Learning Objectives

The aim of this course is to sensitise the attendees about the correct way to recognise, diagnose and treat DTC in children.

Target Audience

Physicians, residents with special interest on endocrinlogy and endo-oncology, nuclear medicine specialists, nurses and technicians of nuclear medicine units.

Suggested Readings

Francis GL, Waguespack SG, Bauer AJ, Angelos P, Benvenga S, Cerutti JM, Dinauer CA, Hamilton J, Hay ID, Luster M, Parisi MT, Rachmiel M, Thompson GB, Yamashita S; American Thyroid Association Guidelines Task Force. Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2015 Jul;25(7):716-59. doi: 10.1089/thy.2014.0460. PMID: 25900731; PMCID: PMC4854274.

Lebbink CA, Links TP, Czarniecka A, Dias RP, Elisei R, Izatt L, Krude H, Lorenz K, Luster M, Newbold K, Piccardo A, Sobrinho-Simões M, Takano T, Paul van Trotsenburg AS, Verburg FA, van Santen HM. 2022 European Thyroid Association Guidelines for the management of pediatric thyroid nodules and differentiated thyroid carcinoma. Eur Thyroid J. 2022 Nov 29;11(6):e220146. doi: 10.1530/ETJ-22-0146. PMID: 36228315; PMCID: PMC9716393.

Czarniecka A, Woźniak G, Kropińska A, Jarząb B, Handkiewicz-Junak D. Surgical approach to differentiated thyroid cancers (DTC) in children [Specyfika leczenia chirurgicznego zróżnicowanych raków tarczycy (ZRT) u dzieci]. Endokrynol Pol. 2019;70(4):357-366. doi: 10.5603/EP.a2019.0033. PMID: 31489960.

Faculty

Desiree DeandreisSpeaker

Catia OliantiModerator

Livia LamartinaSpeaker

Event Overview

Focus on FDG PET/CT in Inflammatory and Infectious Diseases
2025-11-20 09:00 - 2025-11-21 12:30 | Future Health Lab, Alfred-Adler-Straße 1, Vienna, 1100, Austria
Inflammation comes from the Latin word inflammare, to ignite or to set on fire – we want to ignite your interest in imaging inflammation and infection.

Inflammatory and infectious diseases can be clinically challenging. Many are systemic with highly variable clinical presentations and sometimes vague and non-specific symptoms and findings. Association with implanted material like artificial heart valves, joint or vascular prostheses may hamper imaging or give rise to non-specific findings.

Although the imaging strategy may still be considered unclarified in some settings, [18F]FDG-PET/CT is now established as a key modality in the diagnostic workup of several inflammatory and infectious diseases. The course aims to provide the participants with an overview of the evidence and practical use of [18F]FDG-PET/CT in suspected inflammation and infection and covers the most well-established indications.

Led by European experts, the sessions mix short overview lectures with interactive sessions to allow participants to engage in discussions and exchange experiences on daily practices with each other and the faculty.

Register nowThe course is fully booked. Please contact us at esmit@eanm.org if you would like to be added to the waiting list!

Learning Objectives

To provide general insights into the use of [18F]FDG PET/CT in suspected or manifest inflammation and infection, e.g. patient preparation and protocols

To provide insights into how and when to use [18F]FDG PET/CT in suspected or manifest specific inflammatory diseases, e.g. vasculitis, polymyalgia rheumatica, other reumatologic diseases, and sarcoidosis

To provide insights into how and when to use [18F]FDG PET/CT in suspected or manifest specific infectious diseases, e.g. fever and inflammation of unknown origin, blood stream infections, osteomyelitis and spondylodiscitis, cardiac and vascular infections

To provide some insights into novel developments with this domain, e.g. FAPI, bacteria-specific tracers, and long axial field of view scanners

To facilitate an open discussion on pro and cons of [18F]FDG PET/CT in suspected or manifest inflammation and infections

Target Audience

Nuclear medicine specialists with basic experience in reading [18F]FDG-PET/CT in inflammatory and infectious diseases.

ProgrammeView the Programme

Faculty

Soren HessSpeakerOdense, Denmark

Olivier GheysensSpeakerBrussels, Belgium

Ayah NawwarSpeakerBristol, UK

Giorgio TregliaSpeakerLugano, Switzerland

Registration Details

Registration FeeMode of PaymentCancellation Policy

Course Fee € 950.-

Registration Fee includes:

Electronic Course Book, including all Slides

Coffee & Lunch Breaks

Registration Fee does NOT include:

Travel to the Venue

Accommodation

Registration fees need to be paid 1 week prior to the event. In case the payment is not received by this deadline, the registration needs to be cancelled. Payment can be settled by Credit Card Cheques will not be accepted

Cancellations must be notified in writing to the EANM Office. Telephone cancellations cannot be accepted. Substitutions will be accepted if the name and e-mail address of the substitute are sent to the EANM Office 4 weeks prior to the event. In the case of cancellation 4 weeks before the course, we will refund you the fee less a € 100,- administration charge. After this date, we cannot grant any refund for cancellations. Any refund will take place after the respective course. EANM will not be held liable for cancellation fees of hotels, airlines or other means of transportation.

Japanese vs. European View on Targeted Radionuclide Therapy
2025-12-01 10:00 - 11:00
This event is a collaboration between ESMIT and JSNM. The aim of the webinar is to compare the approach to targeted radionuclide therapy (TRT) in Japan and in Europe. The webinar will focus on the differences in the TRT environment in Japan vs. Europe, including regulatory science and radiation protection regulation, and more.

Register nowEnrol in the live webinar now for free! Register now

Target Audience

Nuclear Medicine Physicians

Faculty

Tatsuya HigashiSpeaker

Wolfgang FendlerSpeaker

Conrad-Amadeus VoltinModerator

Event Overview

Nuclear Medicine in Breast Cancer Based on FOCUS Meeting 6
2025-12-04 08:00 - 2025-12-05 17:00 | Future Health Lab, Alfred-Adler-Straße 1, Vienna, 1100, Austria
Breast cancer is the most relevant cancer in women worldwide. It is the second most frequently diagnosed cancer (after lung cancer) and the first leading cause of cancer-related death in women, being the fourth globally regardless of gender. By 2040, breast cancer is predicted to increase to over 3 million new cases and 1 million deaths per year.

Staging patients with breast cancer is challenging due to its heterogeneous nature and presentation. Imaging is of utmost importance in all clinical settings, particularly, in staging, assessing therapy response, and detecting recurrence. Despite the well-stablished usefulness of radiologic modalities, Nuclear Medicine has demonstrated an important role to play in breast cancer, which has been increasingly supported by strong scientific evidence. Considering the patient’s long survival, the benefits of assessing active tumour in an accurate way, gain major importance in these patient’s care.

The recent equipment and radiopharmaceutical developments have opened the path to improve tumour characterization through several imaging possibilities. Currently, the challenge is to use the correct combination of equipment and tracer at the right time. Furthermore, homogenize imaging and clinical procedures is becoming even more important.

During this course, the highlights from the consensus reached during the multidisciplinary EANM Focus Meeting 6 about Nuclear Medicine diagnostics and therapeutics possibilities will be comprehensively presented and discussed in a close way between the faculty and attendees.

Register nowRegistration is now open, save yourself a seat! Register now

Learning Objectives

To understand breast cancer as a heterogeneous disease, its characteristics and evolution;

To define the role of nuclear medicine techniques in different clinical settings (initial staging, assessing therapy response, and detecting recurrence);

To know the potential usefulness of PET tracers beyond FDG in each breast cancer subtype and use of the evolving PET technology & equipment;

To discuss future diagnostic and treatment approaches with radiopharmaceuticals.

Target Audience

Nuclear Medicine physicians, Radiologists, Medical Oncologists, Radiation Oncologists, Medical students, Residents, Nurses, Nuclear Medicine technologists and Radiographers.

ProgrammeView the Programme

Faculty

Sofia VazSpeakerLisbon, Portugal

Thiemo van NijnattenSpeakerMaastricht, Netherlands

Philipp BackhausSpeakerMünster, Germany

Registration Details

Registration FeeMode of PaymentCancellation Policy

Course Fee € 950.-

Registration Fee includes:

Electronic Course Book, including all Slides

Coffee & Lunch Breaks

Registration Fee does NOT include:

Travel to the Venue

Accommodation

Registration fees need to be paid 1 week prior to the event. In case the payment is not received by this deadline, the registration needs to be cancelled. Payment can be settled by Credit Card Cheques will not be accepted

Cancellations must be notified in writing to the EANM Office. Telephone cancellations cannot be accepted. Substitutions will be accepted if the name and e-mail address of the substitute are sent to the EANM Office 4 weeks prior to the event. In the case of cancellation 4 weeks before the course, we will refund you the fee less a € 100,- administration charge. After this date, we cannot grant any refund for cancellations. Any refund will take place after the respective course. EANM will not be held liable for cancellation fees of hotels, airlines or other means of transportation.

To AI or not to AI in Neurology: That is the Question
2025-12-12 13:30 - 14:30
This webinar will explore state-of-the-art AI approaches for advancing neuroimaging, with a particular focus on quantitative PET. It will cover the entire imaging pipeline, from preprocessing, acquisition, and tomographic reconstruction to quantification, segmentation, denoising, and resolution enhancement, demonstrating how modern AI can enable more reproducible and robust brain PET biomarkers. Through two expert presentations and practical case examples, the webinar will showcase how AI-driven methodologies are reshaping neuroimaging research and supporting more accurate diagnosis and disease monitoring.

Register nowEnrol in the live webinar now for free! Register now

Learning Objectives

Learn the principles behind AI-based quantitative PET methods

Understand how AI can enhance each stage of the neuroimaging pipeline, from preprocessing and reconstruction to segmentation, denoising, and resolution recovery.

Critically assess when AI meaningfully improves neuroimaging workflows

Recognize emerging opportunities and challenges in integrating AI tools into brain PET

Target Audience

Nuclear physicians, medical physicists, imaging scientists and radiologists working in PET neuroimaging

Faculty

Pablo Aguilar FernándezModerator

Dimitris VisvikisSpeaker

Charalampos TsoumpasSpeaker

Event Overview

Personalized Medicine in Prostate Cancer: From Diagnostic to Therapy
2026-01-30 00:00 - 2028-01-30 23:59
This course has been accredited with 3 CME credits by the UEMS EACCME.

Radiolabelled prostate-specific membrane antigen (PSMA) is increasingly used in imaging and treatment of prostate cancer. PSMA-directed radionuclide therapy is an efficacious new treatment option in patients with metastatic castration-resistant prostate cancer (mCRPC) and beyond. The online course will cover the spectrum of radiolabelled PSMA tracers, techniques related to PSMA imaging, from diagnosis to therapy, with lectures, interactive case discussions, and relevant information for clinical practice.

Save yourself a seat!Enter the eLearning platform register for the course. Having trouble? See the short tutorial here. Register now!

Learning Objectives

PSMA PET-CT imaging- science and practice:

To provide an overview of clinical applications, normal biodistribution, variants, pitfalls and artefacts in PSMA PET-CT

To learn how to report PSMA PET-CT scans in primary staging and recurrence

Radionuclide PSMA therapy-science and practice (177Lu-PSMA therapies):

To gain knowledge on PSMA patients selection, management of common clinical challenges in implementing and delivering of radionuclide therapies, side effects and their management

To discuss current evidence and trends related to 177Lu-PSMA therapies

To learn about new or emerging targets and radioisotopes for Prostate cancer management

Target Audience

General nuclear medicine specialists, residents, radiologists, healthcare specialists who want to update their knowledge on molecular imaging and radionuclide therapy of prostate cancer including theranostics.

Faculty

Karolien GoffinSpeaker

Wolfgang FendlerSpeaker

Innovations in Theranostics for Neuroblastoma
2026-02-06 13:30 - 14:30
This course provides a comprehensive update on instrumental and radiopharmaceutical innovations in the diagnosis and treatment of neuroblastoma. Participants will explore current and emerging imaging modalities, with a comparative analysis of MIBG, MFBF, FDOPA, and Gallium-based tracers, highlighting their evolving roles in staging, risk stratification, and response assessment.

The course will address recent changes in clinical practice and the challenges these advancements pose for pediatric oncologists and nuclear medicine physicians, emphasizing multidisciplinary decision-making.

In addition, the program will review novel therapeutic strategies for refractory and relapsed neuroblastoma, with a focus on radioligand therapy and its integration with immunotherapy approaches, including CAR-T cell therapy. Through state-of-the-art updates and clinical perspectives, the course aims to equip clinicians with practical insights for optimizing diagnostic accuracy and therapeutic outcomes in this complex pediatric malignancy.

Register nowEnrol in the live webinar now for free! Register now

Learning Objectives

Describe recent instrumental and radiopharmaceutical innovations in the diagnosis and management of neuroblastoma.

Compare the clinical indications, advantages, and limitations of MIBG, MFBF, FDOPA, and Gallium-based imaging tracers in neuroblastoma.

Evaluate how emerging imaging techniques are changing staging, risk stratification, and treatment response assessment in pediatric patients.

Identify current challenges and unmet needs faced by pediatric oncologists and nuclear medicine physicians in integrating new diagnostic tools into clinical practice.

Discuss the principles and clinical applications of radioligand therapy in refractory and relapsed neuroblastoma.

Assess the potential role of combined treatment strategies, including radioligand therapy with immunotherapy and CAR-T cell therapy, in improving patient outcomes.

Apply multidisciplinary decision-making approaches to optimize personalized diagnostic and therapeutic strategies for children with neuroblastoma.

Target Audience

Nuclear Medicine Physicians

Suggested Reading

Se Whee Sammy Park et al. Front Oncol 14:1408729. doi: 10.3389/fonc.2024.1408729 , Lise Borgwardt et al, The Journal of Nuclear Medicine (2024). DOI: 10.2967/jnumed.123.267256

Faculty

Julian RogaschSpeaker

Bart de KeizerSpeaker

Marie LuporsiModerator

Event Overview

Beyond Single Modality: The Future of Cancer Staging with Hybrid Scanners
2026-02-20 13:30 - 14:30
This webinar will be on the future of cancer staging with hybrid imaging technologies. Participants will gain an overview of advanced PET/CT, SPECT/CT, and PET/MRI systems, learning how hybrid imaging enhances diagnostic accuracy and supports more precise clinical decisions.The session will explore the practical challenges technologists face when working with these cutting-edge systems, including image acquisition, processing, and interpretation, while highlighting the technical skills needed for effective operation.We’ll also discuss educational gaps and training opportunities for radiographers and technologists, presenting strategies such as hands-on workshops, e-learning, and mentorship to support professional development.By the end of this webinar, attendees will have a clear understanding of the evolving role of technologists in hybrid oncological imaging and be inspired to embrace innovation, lifelong learning, and interdisciplinary collaboration.

Register nowEnrol in the live webinar now for free! Register now

Learning Objectives

Describe the most advanced hybrid imaging technologies used for oncological staging in nuclear medicine Understand the key features of PET/CT, SPECT/CT, and PET/MRI systems

Distinguish the main advantages and limitations of hybrid modalities in clinical oncology

Understand the added value of multimodality imaging compared with single-modality approaches Identify cases where hybrid imaging improves sensitivity, specificity, or diagnostic accuracy Recognize how functional-anatomical integration supports more precise clinical decisions

Analyze the main challenges faced by technologists in the acquisition, processing, and interpretation of hybrid imaging data Highlight practical issues (e.g., image registration, calibration, artifacts, acquisition timing)Reflect on the technical skills required to operate hybrid systems effectively

Identify educational gaps and learning challenges encountered by radiographers/technologists when adopting new hybrid technologies Recognize organizational, infrastructural, and educational barriers (e.g., equipment availability, supervision, time constraints) Assess variations in training opportunities across European contexts

Propose strategies and training programs for integrating hybrid skills into radiotherapy technician (RTM) programs, fostering critical awareness of the evolving role of the technician in the context of hybrid oncology imaging.Suggest training models (advanced courses, internships at centers of excellence, e-learning, hands-on workshops)Outline a roadmap for continuous development (on-the-job training, certifications, mentorships)

Promote a proactive mindset toward technological innovation and self-development

Target Audience

Nuclear medicine Technologists

Faculty

Oliver RamsaySpeaker

Nia HopsonSpeaker

Paolo TurcoModerator

Event Overview

Radiobiological Aspects of PRRT
2026-03-13 13:30 - 14:30
This webinar will examine the fundamental differences between targeted radionuclide therapy (TRT) and conventional external beam radiotherapy (EBRT), integrating physical, dosimetric, and radiobiological perspectives relevant to clinical practice. Drawing on the EANM–ESTRO joint session, the first part will outline how TRT’s systemic administration, patient-specific pharmacokinetics, protracted low dose-rate delivery, and highly heterogeneous intratumoral distribution distinguish it from the controlled, high dose-rate, fractionated paradigm of EBRT. Emphasis will be placed on implications for treatment planning, activity prescription, imaging-based dosimetry, and the limitations of directly translating EBRT concepts such as uniform dose coverage and standard fractionation models to TRT.

The second part will focus on how absorbed dose, dose rate, and spatial heterogeneity influence biological effectiveness and clinical outcomes in TRT. Key topics include sublethal damage repair during continuous irradiation, challenges in applying conventional radiobiological models, the impact of microscopic dose non-uniformity (especially for β- versus α-emitting therapies), and the relationship between local tumor control and systemic effects, including immune modulation. The session aims to equip nuclear medicine physicians and medical physicists with a conceptual framework to interpret dosimetry results, personalize treatments, and critically evaluate emerging combination strategies as TRT evolves toward a quantitatively driven radiotherapy modality.

Register nowEnrol in the live webinar now for free! Register now

Learning Objectives

Differentiate the fundamental physical and clinical characteristics of TRT versus EBRT, including source geometry, temporal delivery, dose-rate profiles, and implications for treatment planning and prescription.

Explain how pharmacokinetics and biodistribution govern absorbed dose in TRT, and why activity administration alone is an insufficient surrogate for delivered dose and therapeutic effect.

Assess the impact of dose rate and protracted irradiation on radiobiological response, including sublethal damage repair, limitations of conventional linear-quadratic modeling, and consequences for tumor control and normal tissue toxicity.

Recognize the clinical significance of spatial dose heterogeneity at organ, tumor, and cellular scales, particularly differences between β-emitting and α-emitting radiopharmaceutical therapies.

Interpret the relationship between dosimetry metrics and clinical outcomes, including local control, toxicity, and potential systemic (immune-mediated) effects.

Apply these concepts to support patient-specific dosimetry, treatment personalization, and multidisciplinary decision-making in modern targeted radionuclide therapy practice.

Target Audience

This webinar is intended for nuclear medicine physicians and medical physicists involved in targeted radionuclide therapy, including early-career professionals and practitioners seeking to deepen their understanding of the physical and radiobiological principles underpinning modern TRT practice.

Faculty

David Sánchez-ArtuñedoSpeaker

Zachary MorrisSpeaker

Samantha TerryModerator

Event Overview

Dose-Effect Response to Targeted Radionuclide Therapy
2026-03-19 09:00 - 2026-03-20 12:30 | Future Health Lab, Alfred-Adler-Straße 1, Vienna, 1100, Austria
UEMS EACCME has granted the accreditation of 10.5 CME credits for this event.

This intensive 1,5-day course bridges the gap between radiobiology, dosimetry, and clinical practice in targeted radionuclide therapy. Designed for early-career nuclear medicine physicians and medical physicists, the programme explores dose-response relationships in the three most commonly used theranostic molecules: somatostatin-ligands for neuroendocrine tumours, PSMA-inhibitors for prostate cancer, and radioiodine for thyroid malignancies.

Through a balanced faculty of radiobiologists, dosimetry experts, and experienced nuclear medicine physicians, participants will gain practical insights into the biological effects of radiation, dosimetry calculation methodologies, and their clinical implementation. The course emphasizes hands-on learning through joint case sessions, interactive workshops, and patient-specific treatment planning exercises.

Format: Lectures, case discussions, interactive workshops, and panel sessions

Register nowThe registration is closed.

Learning Objectives

At the end of the two days, participants of the course will be able to:

Explain the fundamental radiobiological principles underlying dose-effect relationships in targeted radionuclide therapy and how they differ from external beam radiotherapy and brachytherapy.

Describe the complete workflow from imaging acquisition to dose calculation and apply core dosimetry concepts to clinical TRT scenarios.

Integrate dosimetry data into clinical decision-making for patient selection, treatment planning, and outcome prediction in targeted radionuclide therapy.

Compare and contrast the clinical applications, dose-response characteristics, and dosimetric considerations for somatostatin-ligand therapy (neuroendocrine tumours), PSMA-inhibitor therapy (prostate cancer), and radioiodine therapy (thyroid disease).

Interpret key clinical trial outcomes and evidence-based data related to dosimetry-guided TRT across the three major theranostic applications.

Design a patient-specific TRT treatment plan incorporating radiobiological principles, dosimetric calculations, and clinical considerations for organ protection and tumour targeting.

Identify the practical challenges and solutions for implementing dosimetry protocols in routine clinical nuclear medicine practice.

Critically evaluate when and how personalized dosimetry can optimize therapeutic outcomes and minimize toxicity in individual patients.

Target Audience

Early-career nuclear medicine doctors and medical physicists

ProgrammeView the Programme

Faculty

Julie NonnekensSpeakerNetherlands

Lars Tore Gyland MikalsenSpeakerNorway

Francesco CiconeSpeakerItaly

Francesco GiammarilleSpeakerFrance

Registration Details

Registration FeeMode of PaymentCancellation Policy

Course Fee € 950.-

NEW Department Package: If you send 5 participants from your department, you will get an additional 6th seat for free for this course. Please get in touch with the ESMIT office if this is of interest to you.

Registration Fee includes:

Electronic Course Book, including all Slides

Coffee & Lunch Breaks

Registration Fee does NOT include:

Travel to the Venue

Accommodation

Registration fees need to be paid 1 week prior to the event. In case the payment is not received by this deadline, the registration needs to be cancelled. Payment can be settled by Credit Card. Cheques will not be accepted

Cancellations must be notified in writing to the EANM Office. Telephone cancellations cannot be accepted. Substitutions will be accepted if the name and e-mail address of the substitute are sent to the EANM Office 4 weeks prior to the event. In the case of cancellation 4 weeks before the course, we will refund you the fee less a € 100,- administration charge. After this date, we cannot grant any refund for cancellations. Any refund will take place after the respective course. EANM will not be held liable for cancellation fees of hotels, airlines or other means of transportation.

FDG PET/CT in Inflammation and Infection: from Theory to Clinical Practice!
2026-03-27 13:30 - 14:30
Imaging of infection and inflammation has been part of nuclear medicine since the 1970s. Over the past two decades, the growing role of FDG PET/CT in diagnosing and monitoring the treatment of a wide variety of infectious and inflammatory diseases has been recognised. As a result, this technique has recently been adopted in several clinical guidelines. This webinar provides clinical case-based evidence to assist nuclear medicine physicians in recommending, performing and interpreting FDG PET/CT examinations in patients with infectious and inflammatory disorders.

Register nowEnrol in the live webinar now for free! Register now

Learning Objectives

The aim of this live webinar is to describe, using illustrative clinical cases, the role of FDG PET/CT in a variety of pathological conditions characterised by infection or inflammation, with particular emphasis on strengths and limitations of FDG PET/CT.

Target Audience

Nuclear Medicine Physicians, Residents, Technologists

Faculty

Ayah NawwarSpeaker

Domenico AlbanoSpeaker

Søren HessSpeaker

Lucia LeccisottiModerator

Event Overview

Open your Heart on SPECT and PET Studies: Synergistic Information from the CT
2026-04-10 13:30 - 14:30
This webinar will cover synergetic information derived from the CT component in SPECT/CT and PET/CT examinations: the first part we will focus on cardiac calcifications, offering valuable insights into their detection and clinical relevance especially for myocardial perfusion scans. In the second half, we will discuss incidental findings in the thorax, helping clinicians recognize and interpret unexpected observations in SPECT/CT and PET/CT studies.

Register nowEnrol in the live webinar now for free! Register now

Learning Objectives

This webinar aims to equip attendees with practical knowledge that enhances diagnostic confidence, facilitates interdisciplinary collaboration, and improves patient outcomes in hybrid nuclear cardiology examination. Participants will gain a deeper understanding of:

Cardiac Calcifications with CT: Learn how to identify and assess cardiac calcifications using CT imaging, recognize their clinical significance, and understand their implications for cardiovascular disease risk stratification in PET/CT and SPECT/CT myocardial perfusion examinations

Incidental Findings in the Thorax: Develop the ability to systematically evaluate incidental thoracic findings encountered in SPECT/CT and PET/CT studies, differentiate between benign and pathological abnormalities, and enhance decision-making for further clinical assessment.”info will come soon

Target Audience

Nuclear Medicine physicians, Cardiologists with focus on cardiovascular imaging, Radiologists, Technologists, Residents in Nuclear Medicine.

Faculty

Manar BadarnahSpeaker

Christoph RyffelSpeaker

Federico CaobelliModerator

Event Overview

Nuclear Medicine in FUO/IUO: Why Are Children Different?
2026-04-16 09:00 - 2026-04-17 12:30 | Future Health Lab, Alfred-Adler-Straße 1, Vienna, 1100, Austria
This 1,5-day course focuses on the growing field of integrated imaging in infectious and inflammatory diseases in children, with an emphasis on hybrid imaging.

The panelists will introduce the participants to the specific aspects of paediatric patients in this growing field, covering the most relevant topics of the clinical scenario and the technical options available in daily practice.

The participants will be confronted with frequent and less frequent disease pattern, with ample opportunity for discussing clinical indications and image interpretation criteria.

The continuing interaction between paediatrician, paediatric radiologist and nuclear medicine physician will show the practical implementation of an integrated approach, with particular attention to radiation dose reduction and optimisation.

RegistrationThe registration for this course is closed. Please get in touch with us at esmit@eanm.org if you still want to register.

Learning Objectives

After the course the participants will be able to:

Describe the impact of new imaging modalities on the clincial workup of infectious and inflamamtory diseases in children

Identify the most relevant indications for hybrid imging in paediatric inflammatory and infectious diseases in children

Describe the different protocols for FDG imaging, selecting the most indiated depending on age group and clinical setting

Define the correct workflow for integrated imaging in different clinical situations, with particular regard to radiation dose optimisation

Target Audience

Physicians, residents with special interest in paediatrics, nuclear medicine, radiology, nurses and technicians of nuclear medicine or radiology unit.

ProgrammeView the Programme

Faculty

Pietro ZucchettaSpeakerPadova, Italy

Sandra TrapaniSpeakerFlorence, Italy

Chiara GiraudoSpeakerPadova, Italy

Registration Details

Registration FeeMode of PaymentCancellation Policy

Course Fee € 950.-

NEW Department Package: If you send 5 participants from your department, you will get an additional 6th seat for free for this course. Please get in touch with the ESMIT office if this is of interest to you.

Registration Fee includes:

Electronic Course Book, including all Slides

Coffee & Lunch Breaks

Registration Fee does NOT include:

Travel to the Venue

Accommodation

Registration fees need to be paid 1 week prior to the event. In case the payment is not received by this deadline, the registration needs to be cancelled. Payment can be settled by Credit Card. Cheques will not be accepted

Cancellations must be notified in writing to the EANM Office. Telephone cancellations cannot be accepted. Substitutions will be accepted if the name and e-mail address of the substitute are sent to the EANM Office 4 weeks prior to the event. In the case of cancellation 4 weeks before the course, we will refund you the fee less a € 100,- administration charge. After this date, we cannot grant any refund for cancellations. Any refund will take place after the respective course. EANM will not be held liable for cancellation fees of hotels, airlines or other means of transportation.

Dosimetry in Clinical Trials
2026-05-08 13:30 - 14:30
More info will come soon

Register nowEnrol in the live webinar now for free! Register now

Learning Objectives

More info will come soon

Target Audience

More info will come soon

Faculty

SpeakerSpeaker

SpeakerSpeaker

SpeakerModerator

Event Overview

FAP and Stroma Imaging – Current and Future Applications
2026-05-29 13:30 - 14:30

Bringing Therapy Radioisotopes into Clinical Radiopharmacy – Some Regulatory Aspects
2026-06-11 09:00 - 2026-06-12 12:30 | Future Health Lab, Alfred-Adler-Straße 1, Vienna, 1100, Austria
“Bringing Therapy Radioisotopes into Clinical Radiopharmacy” is an advanced course designed to bridge the gap between isotope production, radiopharmaceutical preparation and clinical application. This course focuses on the practical and regulatory hurdles of integrating therapeutic radionuclides into hospital settings.

Diving into production and purification methods of emerging therapeutic isotopes, supply chain and matched pairs for theranostics, we’ll then navigate the regulatory landscape (cGMP, marketing authorizations, and clinical trials). Understanding how the radiometals and radiohalogens used in therapy are used for radiopharmaceutical preparation correlates with quality control standards specific to alpha and beta emitters.

We will focus on transitioning from a research lab to a clinical radiopharmacy, revising documentation requirements and facility design for high-energy beta and alpha particles, and also safety protocols for pharmacists, radiochemists and technicians.

This course provides the blueprint for establishing a modern, therapy-ready radiopharmacy, moving beyond diagnostic imaging into the era of personalized molecular radiotherapy.

Register nowRegistration is now open, save yourself a seat! Register now

Learning Objectives

General knowledge regarding GMP and cGMP for Radiopharmaceuticals principles and guidelines.

Target Audience

Hospital and production radiopharmacists, and radiochemists involved in clinical trials with radiopharmaceuticals, hospital radiopharmacy and radiopharmaceutical production.

ProgrammeView the Programme

Faculty

Dana NiculaeSpeakerBucharest, Romania

Neil HartmanSpeakerSwansea Bay, UK

Antero AbrunhosaSpeakerCoimbra, Portugal

Registration Details

Registration FeeMode of PaymentCancellation Policy

Course Fee € 950.-

NEW Department Package: If you send 5 participants from your department, you will get an additional 6th seat for free for this course. Please get in touch with the ESMIT office if this is of interest to you.

Registration Fee includes:

Electronic Course Book, including all Slides

Coffee & Lunch Breaks

Registration Fee does NOT include:

Travel to the Venue

Accommodation

Registration fees need to be paid 1 week prior to the event. In case the payment is not received by this deadline, the registration needs to be cancelled. Payment can be settled by Credit Card. Cheques will not be accepted

Cancellations must be notified in writing to the EANM Office. Telephone cancellations cannot be accepted. Substitutions will be accepted if the name and e-mail address of the substitute are sent to the EANM Office 4 weeks prior to the event. In the case of cancellation 4 weeks before the course, we will refund you the fee less a € 100,- administration charge. After this date, we cannot grant any refund for cancellations. Any refund will take place after the respective course. EANM will not be held liable for cancellation fees of hotels, airlines or other means of transportation.

Navigating International Guidelines for the Management of Thyroid Cancer
2026-06-19 13:30 - 14:30
